Want to see TSE:ASG full AI Analyst Report?
ASG Stock Chart & Stats
C$0.28
>-C$0.01(-1.05%)
At close: 4:00 PM EST
C$0.28
>-C$0.01(-1.05%)
Day’s Range― - ―
52-Week RangeC$0.21 - C$0.36
Previous CloseN/A
Volume6.50K
Average Volume (3M)30.19K
Market Cap
C$19.91M
Enterprise ValueC$12.84M
Total Cash (Recent Filing)C$778.55K
Total Debt (Recent Filing)C$2.26M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding78,092,200
10 Day Avg. Volume38,837
30 Day Avg. Volume30,190
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)4.02
Price to Sales (P/S)0.83
P/FCF Ratio36.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationA sustained shift to positive operating and free cash flow provides durable internal funding for working capital, R&D and commercialization without immediate reliance on dilutive financing. Over 2-6 months this improves runway, reduces liquidity risk and supports strategic execution.
Manageable LeverageLow debt-to-equity indicates the company has room to fund operations or opportunistic investments and is less exposed to interest or covenant stress. This balance sheet flexibility supports operational continuity and strategic choices over the medium term while revenue recovery is pursued.
High Gross Margin And Positive EBITDAA strong gross margin and a return to positive EBITDA signal resilient product economics and initial operating leverage. If revenue stabilizes, these margins allow incremental sales to flow to the bottom line, making profitability achievable without wholesale cost restructuring.
Bears Say
Sharp Revenue DeclineA near-30% TTM revenue drop is a structural threat to margin leverage and scale economics. Persistent top-line weakness can erode market positioning, impair fixed-cost absorption and limit the impact of positive unit margins, making operational recovery critical in coming months.
Ongoing Net LossesContinued net losses mean the company is not yet converting positive cash or EBITDA into shareholder profits. Over a multi-month horizon this constrains retained earnings, raises dependence on external capital for growth, and keeps investor return prospects uncertain until sustained profitability.
Negative Returns On EquityA deeply negative ROE shows capital employed is destroying shareholder value. This undermines investor confidence and can increase cost of capital, limiting options for funding product development or sales expansion until operational performance and net income turn positive.
Aurora Spine News
ASG FAQ
What was Aurora Spine Corp’s price range in the past 12 months?
Aurora Spine Corp lowest stock price was C$0.20 and its highest was C$0.35 in the past 12 months.
What is Aurora Spine Corp’s market cap?
Aurora Spine Corp’s market cap is C$19.91M.
When is Aurora Spine Corp’s upcoming earnings report date?
Aurora Spine Corp’s upcoming earnings report date is Aug 26, 2026 which is in 56 days.
How were Aurora Spine Corp’s earnings last quarter?
Currently, no data Available
Is Aurora Spine Corp overvalued?
According to Wall Street analysts Aurora Spine Corp’s price is currently Overvalued.
Does Aurora Spine Corp pay dividends?
Aurora Spine Corp does not currently pay dividends.
What is Aurora Spine Corp’s EPS estimate?
Aurora Spine Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aurora Spine Corp have?
Aurora Spine Corp has 78,092,200 shares outstanding.
What happened to Aurora Spine Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aurora Spine Corp?
Currently, no hedge funds are holding shares in TSE:ASG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aurora Spine Corp
Established in 2013 and headquartered in Toronto, Canada, Aurora Spine Corporation, through its subsidiary Aurora Spine, Inc., specializes in the development and distribution of advanced, minimally invasive spinal fusion systems and devices within the Canadian market. The company offers a comprehensive portfolio of products designed to address various spinal conditions, particularly degenerative disc diseases. This includes interspinous process lumbar fusion devices such as the ZIP series (ZIP, ZIP ULTRA, ZIP LP, and ZIP-51). Aurora Spine also provides Ti-Coated polyether ether ketone (PEEK) interbody cages, which are crucial for maintaining space and stability between vertebrae while facilitating bone fusion. Its offerings extend to sterile-packed titanium plasma spray coated spinal fusion implants that promote bone growth. Key interbody products comprise EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar region, and Discovery for cervical applications. The company also manufactures SOLO, an anterior lumbar interbody fusion (ALIF) 3D-printed stand-alone device featuring an integrated plate and spacer system for anatomical preservation and spinal support. For sacroiliac joint issues, Aurora Spine provides SiLo, a posterior fusion device. Furthermore, the DEXA-C cervical interbody system, a porous 3D-printed intervertebral body fusion device with customizable lattice density options, is available to match patient bone quality.
Technical Analysis
Perimeter Medical Imaging AI
―
―
Theralase Technologies
―
VentriPoint Diagnostics
―
―
Options Prices
Currently, No data available
---